FDA Approves First Over-the-Counter Combo Flu and COVID Test Outside of Emergency Use

The U.S. Food and Drug Administration (FDA) has authorized the first over-the-counter combination COVID-19 and influenza test, the Healgen Rapid Check COVID-19/Flu A&B Antigen Test, outside of emergency use.
Updated COVID Vaccines Approved by FDA

FDA has approved and granted emergency use authorization for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent (single) component that corresponds to the Omicron variant KP.2 strain of SARSCoV-2.
Scientists Develop $25 Nasal Spray That Is 99% Effective Against Colds, Flu and COVID-19

Scientists at Harvard Medical School have developed a simple nasal spray, made of harmless ingredients, that can protect people against flu, colds and COVID-19 with near-100 percent success, and it costs just $25.
CDC Identifies New COVID Strain Known as XEC

A newly discovered COVID strain known as XEC continues to spread rapidly across multiple countries, including the U.S.
Updated COVID Vaccines Approved by FDA

The U.S. Food and Drug Administration (FDA) has approved and granted emergency use authorization for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent (single) component that corresponds to the Omicron variant KP.2 strain of SARS-CoV-2.
Nasal COVID-19 Vaccine Halts Transmission of SARS-CoV-2

A study by researchers at Washington University School of Medicine in St. Louis indicates next-generation vaccines that target a virus’s points of entry — the nose and mouth — may be able to contain the spread of respiratory infections and prevent transmission.
COVID Vaccines: What’s Available Now and What’s in the Works?

Three top vaccine producers are making newer vaccines that not only protect against the newer sublineages of COVID-19, but that also protect against other respiratory viruses.
Nasal COVID-19 Vaccine Trial Opens

A Phase I clinical trial testing the safety of an experimental nasal vaccine, MPV/S-2P, that may provide enhanced breadth of protection against emerging variants of SARS-CoV-2, the virus that causes COVID-19, is now enrolling healthy adults at three sites in the United States.
Study Shows Positive Results for mRNA-Based Combination Influenza and COVID-19 Vaccine

A Phase I/II study evaluating the safety, tolerability and immunogenicity of Pfizer and BioNTech’s mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age show positive topline results.
HHS Awards $45 Million in Grants to Expand Access to Care for People with Long COVID

The U.S. Department of Health and Human Services announced nine grant awards $1 million each for up to five years to support existing multidisciplinary Long COVID clinics across the country.